Fujifilm Invests $83M to Expand Microbial Capacity

Fujifilm Corporation has unveiled plans to invest approximately $83 million to expand the microbial production capacity of Fujifilm Diosynth Biotechnologies (FDB), a cGMP contract development and manufacturing organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies. The expansion will be made in its UK site and is scheduled to be operational after 2022. It will triple FDB's current capacity of microbial production at the UK site.
 
Fujifilm's investment in the UK site will allow FDB to respond to the increased demand of microbial expressed therapies. The expansion will include a new production line equipped with 2 X 2000L fermenters and a modular purification suite. The utilities at the facility will be upgraded to accommodate for high volume production.
 
"Fujifilm has committed to supporting the biopharmaceutical industry and invested aggressively in both capital and technology for producing such as antibodies and gene therapies," said Takatoshi Ishikawa, executive vice president, general manager of bio CDMO division of Fujifilm Corporation. "We respond to the increased demand of microbial production this time and will continue to contribute to the industry."
 
Paul Found, chief operating officer, FDB, UK, said, "For more than 30 years FDB has been a leader in microbial production. From our pAVEway expression technology to our commercial capabilities, we are well suited to support customers at all stages of the product development process. This expansion will cement our position as the leading microbial CDMO."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.